Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor

•Gilbert's syndrome testing is needed for post-ETI hyperbilirubinemia.•ETI therapy is safe for Gilbert's syndrome-related hyperbilirubinemia.•More research is needed to understand causality and mechanisms.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cystic fibrosis 2023-11, Vol.22 (6), p.1130-1132
Hauptverfasser:	Terlizzi, V., Timpano, S., Salvi, M., Tosco, A., Castaldo, A., Fevola, C., Leonetti, G., Vitullo, P., Sepe, A., Badolato, R., Salvatore, D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminophenols - adverse effects Benzodioxoles - adverse effects Chloride Channel Agonists - adverse effects Cystic Fibrosis - complications Cystic Fibrosis - drug therapy Cystic Fibrosis - genetics Cystic Fibrosis Transmembrane Conductance Regulator - genetics Drug Combinations Gilbert Disease - diagnosis Gilbert Disease - drug therapy Gilbert Disease - genetics Humans Hyperbilirubinemia Mutation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Gilbert's syndrome testing is needed for post-ETI hyperbilirubinemia.•ETI therapy is safe for Gilbert's syndrome-related hyperbilirubinemia.•More research is needed to understand causality and mechanisms.
ISSN:	1569-1993 1873-5010 1873-5010
DOI:	10.1016/j.jcf.2023.06.013